Curis’ licensed emavusertib shows efficacy in lymphoma trial

Curis announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma – PCNSL – patients. As of October 12th, the TakeAim Lymphoma trial has enrolled and treated 19 Non-Hodgkin Lymphoma – NHL – patients, with a combination of emavusertib and ibrutinib; with emavusertib doses ranging from 100 mg to 300 mg BID. The initial data reveal “encouraging” efficacy, demonstrating multiple objective responses in both BTK-naive and BTK-experienced patients. 3 out of 5 evaluable PCNSL patients achieved a Complete Response, with durability ranging from 0.3 – 8.9 months. Consistent with previous findings, the emavusertib/ibrutinib combination demonstrates a manageable and acceptable safety profile, with no observed dose-limiting toxicities in the 200 mg cohort and 2 reversible DLTs in the 300 mg cohort. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib.